Canine pyometra and prostatic disease both live in the reproductive system, both carry real morbidity, and both show up on the NAVLE with very predictable question patterns. Pyometra questions test your ability to recognize open vs. closed, know when to cut, and understand the PU/PD mechanism. Prostatic questions test whether you know which conditions happen in intact vs. castrated males — and the carcinoma trap is one of the most classic wrong-answer pitfalls on the exam.
Pyometra: Pathophysiology
Pyometra develops because of progesterone. During diestrus, progesterone primes the uterus for pregnancy — it drives cystic endometrial hyperplasia (CEH), suppresses myometrial contractions, and blunts local immune defenses. Bacteria, usually E. coli ascending from the vagina, exploit that environment. The classic presentation is an intact female, typically middle-aged to older, presenting 4–10 weeks post-estrus.
The CEH-pyometra complex is a continuum: CEH comes first from repeated progesterone exposure, and secondary bacterial infection converts it to true pyometra. This is why the condition is rare in young dogs and far more common in multiparous females who have had many diestrus cycles without pregnancy.
Open vs. Closed Pyometra
The cervix determines everything about clinical presentation and urgency.
Open pyometra: Cervix remains partially open → purulent or mucopurulent vaginal discharge is the cardinal sign. These patients are often less systemically ill, though they can still be septic. The discharge is a visual giveaway the exam will use.
Closed pyometra: Cervix is shut. No discharge. Pus accumulates under pressure, endotoxins absorb systemically, and these animals deteriorate fast. Endotoxemia, uterine rupture, peritonitis, renal failure — closed pyometra is a true emergency. On the NAVLE, if the dog is critically ill and there is no discharge, think closed pyometra first.
Clinical Signs and Diagnostics
The PU/PD in pyometra is a classic board question. The mechanism is endotoxin-mediated nephrogenic diabetes insipidus — E. coli endotoxin interferes with ADH receptor signaling in the renal tubules, not the hypothalamus or pituitary. The dog makes ADH normally, but the tubules cannot respond. Importantly, this resolves after OHE. If a question asks about PU/PD in a pyometra dog, the answer is not primary renal disease.
Other clinical signs: vomiting, lethargy, anorexia, fever or hypothermia (late sepsis), abdominal distension. Labs: leukocytosis with left shift, toxic neutrophils, elevated BUN/creatinine (pre-renal ± intrinsic renal from endotoxin), hyperglobulinemia. Abdominal radiograph or ultrasound shows a fluid-filled, tubular uterine structure.
Treatment
OHE is definitive. For sick animals, stabilize first — IV crystalloids to correct dehydration, broad-spectrum antibiotics (amoxicillin-clavulanate or ampicillin-sulbactam cover the typical gram-negative and gram-positive flora), then take to surgery. Do not delay surgery waiting for a fully stable patient in closed pyometra; the uterus is the source, and it has to come out.
Medical management with prostaglandin F2α (dinoprost, 0.1–0.25 mg/kg SQ) causes myometrial contraction and corpus luteum lysis, evacuating the uterus. Reserve it strictly for: open pyometra, clinically stable dog, valuable breeding animal, owner fully informed of the high relapse rate (>50%). Side effects are significant — tachycardia, salivation, defecation, vomiting, and transient discomfort within minutes of injection. Aglepristone (progesterone receptor antagonist) is used in combination in some protocols but is not widely available in North America.
Prostatic Disease: Know Your Patient's Status
Intact vs. castrated status drives almost every prostatic disease question on the board. The table below is the framework:
BPH
Benign prostatic hyperplasia develops in virtually all intact male dogs by age 6–9 years. It is androgen-driven — dihydrotestosterone (DHT, converted from testosterone by 5-alpha reductase in prostatic tissue) drives stromal and glandular proliferation. The hallmark is symmetric, non-painful prostatomegaly. Clinical signs are mild: hematuria, hemospermia, ribbon-like stools from rectal compression. These dogs are not systemically ill.
Castration causes rapid prostatic regression — the gland shrinks to about 70% of its pre-castration size within weeks. Finasteride (5-alpha reductase inhibitor) is the alternative for breeding animals. It blocks DHT synthesis and reduces gland size, but the effect reverses when the drug is stopped.
Acute Prostatitis
Bacterial prostatitis is most commonly E. coli, ascending from the urethra. The prostate is painful on rectal palpation, the dog is febrile and systemically ill. Culture the urine and, if safe, the prostatic fluid (from prostatic massage or ejaculation).
Antibiotic selection is critical. The blood–prostate barrier limits drug penetration into normal prostatic tissue. Drugs that cross the barrier effectively include: trimethoprim-sulfonamide, enrofloxacin, and chloramphenicol. These are lipophilic, weak bases that concentrate in the slightly acidic prostatic fluid. Amoxicillin, ampicillin, and most beta-lactams do not penetrate adequately — they are the classic wrong answers on an antibiotic-selection question for prostatitis.
Prostatic Abscess
Usually a sequela of chronic prostatitis. The prostate is asymmetrically enlarged, painful, and fluctuant on rectal exam. Rupture causes peritonitis and septic shock. Treatment is surgical drainage (omentalization or marsupialization) plus prolonged antibiotics (barrier-penetrating drugs, typically 6–8 weeks) plus castration if intact. Castration alone without drainage is insufficient and dangerous.
Prostatic Carcinoma
Prostatic adenocarcinoma is the malignancy to know. It is locally invasive and metastasizes early — to sublumbar lymph nodes, lumbar vertebrae, and lungs. Classic presentation: older dog (intact or castrated) with hindlimb weakness, a fixed asymmetric prostate on rectal exam, and possibly urethral obstruction. Radiograph shows irregular prostatic mineralization and sometimes vertebral lesion.
Prognosis is poor regardless of therapy. NSAIDs (particularly piroxicam) provide some palliative benefit. Surgery is rarely curative given early metastasis. Median survival after diagnosis is measured in weeks to a few months.
Drug Mechanism Flow: Finasteride for BPH
5α-reductase inhibitor
reversible with drug